Dr. Agarwals Healthcare IPO: To Buy or Not to Buy?

Dr. Agarwals Healthcare has opened its Initial Public Offering (IPO) today, with shares priced between ₹382 and ₹402. The IPO will remain open until January 31, 2025. Investors are keenly watching the Grey Market Premium (GMP), which is currently trading at a ₹12 premium, indicating a potential listing price of ₹414 per share.

The total issue size is ₹3,027.26 crores, which includes a fresh issue of ₹300 crores and an offer for sale of ₹2,727.26 crores. Anchor investors have already subscribed to the issue, infusing ₹875.50 crores.

Retail investors can apply for a minimum of 35 shares, requiring a ₹14,070 investment. The allotment date is set for February 3, 2025, with the listing date scheduled for February 5, 2025.

Dr. Agarwals Healthcare operates a network of 209 eye care facilities in India and abroad. With plans to repay debt and fund general corporate purposes, the company aims to leverage the IPO proceeds for its growth.

Should investors subscribe? The IPO’s attractiveness depends on the company’s ability to capitalize on the growing eye care market in India.